Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 87
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 83
Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates
Murugaiah A. M. Subbaiah, Jarkko Rautio, Nicholas A. Meanwell
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 2099-2210
Closed Access | Times Cited: 25
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5351-5372
Closed Access | Times Cited: 12
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S. Scott, Thomas G. Hayhow, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13106-13116
Closed Access | Times Cited: 12
Repurposing AS1411 for constructing ANM-PROTACs
Xuekun Fu, Jin Li, Xinxin Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1290-1304.e7
Closed Access | Times Cited: 10
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Tomasz Sobierajski, Joanna Małolepsza, Marta Pichlak, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104032-104032
Open Access | Times Cited: 9
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12559-12585
Open Access | Times Cited: 19
Rapid PROTAC Discovery Platform: Nanomole-Scale Array Synthesis and Direct Screening of Reaction Mixtures
Mateusz P. Plesniak, Emilia K. Taylor, Frederik Eisele, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1882-1890
Closed Access | Times Cited: 18
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)
Janis Niessen, Jenny M. Nilsson, Karsten Peters, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 249, pp. 116348-116348
Open Access | Times Cited: 6
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report
Xavier Pépin, Sumit Arora, Luiza Borges, et al.
Molecular Pharmaceutics (2024)
Open Access | Times Cited: 5
Heterobifunctional small molecules to modulate RNA function
Sandra Kovachka, Yuquan Tong, Jessica L. Childs‐Disney, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 449-463
Closed Access | Times Cited: 4
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Paige J. Monsen, Prashant V. Bommi, Arabela A. Grigorescu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Paige J. Monsen, Prashant V. Bommi, Arabela A. Grigorescu, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Application of DELs for E3 Ligase Ligand Discovery and Targeted Protein Degradation
Marie L. Malone, Nicholas A. Sanchez, Shimin Hu, et al.
Royal Society of Chemistry eBooks (2025), pp. 134-156
Closed Access
In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©
Christine K. Maurer, Zhizhou Fang, Christina Schindler, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability
Vasanthanathan Poongavanam, Stefan Peintner, Yordanos Esubalew Abeje, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
Exploring chemical space for “druglike” small molecules in the age of AI
Aman Achuthan Kattuparambil, Dheeraj Kumar Chaurasia, Shashank Shekhar, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
Page 1 - Next Page

Scroll to top